Skip to content
← Index board

Health Optimization Index

Ephedrine

Nick’s assessment
Experimental
Research evidence
B, good evidence
Attention
13.3 / 100▲ Rising this week
5/ 10

BioHarmony score

Ephedrine produces modest weight loss (about 0.9 kg/month per Shekelle 2003 JAMA) and a real ergogenic boost (+39% time-to-exhaustion in Bell 1998) but carries a multi-pathway multi-pathway intrinsic life-threatening risk profile: sudden cardiac death, stroke, heatstroke, and hypertensive crisis with MAOIs are documented at therapeutic doses. The 2004 FDA dietary-supplement ban remains in force.

Read the full report Benefits, risks and practical guidance.

Read Nick’s assessment Why it earned this rating

Ephedrine is a 5.0–5.5/10 fit for people considering body composition, energy, respiratory, endurance cardio, with the strongest case in the populations already represented by the evidence rather than broad wellness use. Shekelle 2003 and Shekelle 2003 give the report its main anchors. The benefits are context-dependent and the evidence still leaves responder, dose, and long-term questions open. Ephedrine makes the most sense when the target is concrete, such as a lab marker, symptom pattern, training limitation, or recovery bottleneck. It makes less sense as a background habit taken on faith. In practice, treat Ephedrine as a tracked experiment: define the outcome first, watch for tradeoffs, and let the response decide whether it earns a place.

✅ Best for: Time-bound (4-8 week) cutting protocols in screened adults without cardiovascular risk factors, MAOI/SSRI/TCA exposure, hyperthyroidism, BPH, narrow-angle glaucoma, seizure history, or pregnancy. Pharmaceutical-grade ephedrine HCl behind the pharmacy counter, never gray-market herbal ephedra. Anesthesiologists using ephedrine sulfate IV for spinal-anesthesia hypotension under medical supervision. Adults with mild bronchospasm without access to beta-2 selective inhalers. The narrow indication window is deliberate.

❌ Avoid if: You have any history of coronary artery disease, arrhythmia, hypertension, stroke, heart failure, or cardiomyopathy. You take MAOIs (absolute contraindication), SSRIs, SNRIs, TCAs, beta-blockers, halothane anesthesia, theophylline, or linezolid. You have hyperthyroidism, pheochromocytoma, BPH, narrow-angle glaucoma, diabetes with autonomic neuropathy, anxiety disorder, panic disorder, or a seizure history. You are pregnant or breastfeeding. You exercise in heat above 80°F. You are over 65 or under 18. You have a history of substance use disorder. You can access GLP-1 agonists, modafinil, or beta-2 inhalers as alternatives for the indication you were considering ephedrine for.

Share your experience

Your answers are optional and help other readers — they never change my score. How community input works.

Tried it in real life?

How would you assess it?

Favorable is the strongest rating, followed by Promising, then Experimental. Overhyped means the claims outrun the evidence or interest is fading.

Make a 12-month prediction Will it rise or fall in the Index?

Choose a direction and your confidence. Correct predictions earn leaderboard points.

Your 12-month call on Ephedrine
How sure are you?

Your prediction is final once submitted. We’ll check it in 12 months. See the leaderboard →

Updated Sep 19, 2026 How the Index ranks →

Educational information, not medical advice. Ask a qualified clinician about risks and interactions. Independent ratings: no affiliate links, sponsored placements or paid rankings.